Promomed Group received approval for a new antitumor drug for the treatment of the most common types of cancer

Docetaxel became the seventh drug in the company's anti-cancer portfolio.

The drug belongs to the first-line drug products for the treatment of breast cancer, metastatic prostate and stomach cancer, unresectable non-small cell lung cancer, and malignant tumors of the head and neck; it is also a second-line drug for the treatment of metastatic ovarian cancer. It is used both in monotherapy and in combination with other antitumor drugs. It is also used when therapy with anthracycline* drugs is ineffective.

Docetaxel belongs to the class of taxane agents, which are cytostatic** medicinal products of plant origin; it is produced by chemical synthesis from the needles of the European yew. The mechanism of action of the drug consists in the accumulation of a special protein tubulin in the nuclei of tumor cells, which leads to disruption of cell division processes and causes their death.

In addition, docetaxel remains in cells for a long time and is active against some cells that cannot be treated with many other chemotherapy drugs.

The development of the anti-cancer portfolio is one of the priority areas for the Promomed Group as part of the strategy of solving global medical problems, saving lives and significantly improving the health of patients.

Docetaxel-Promomed will be produced in the form of concentrate for the preparation of solution for infusion. This dosage form is more effective on tumors, reducing the overall toxic effect on the body.

Docetaxel it is included in the VED list, just like most medicines from the anti-cancer portfolio of the Promomed Group.

*Anthracycline drugs are antitumor antibiotics.

**Cytostatic drugs are antitumor drugs that disrupt the growth and development and interfere with the mechanisms of cell division of all cells of the body, including malignant ones, thereby initiating apoptosis. Cytostatics mainly affect cells with a high mitotic index, or cells which biochemical processes are most prone to destabilization by these agents.